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Tissue engineering of heart valves using decellularized
xenogeneic or polymeric starter matrices
Abstract
Heart valve replacement represents the most common surgical therapy for end-stage valvular heart
diseases. A major drawback that all contemporary heart valve replacements have in common is the lack
of growth, repair and remodelling capability. In order to overcome these limitations, the emerging new
field of tissue engineering is focusing on the in vitro generation of functional, living heart valve
replacements. The basic approach uses starter matrices either of decellularized xenogeneic or polymeric
materials configured in the shape of the heart valve and subsequent cell seeding. This manuscript will
give a detailed overview of these two concepts without giving favour to one or the other. The
concluding discussion will focus on current limitations and studies as well as future challenges prior to
safe clinical application.
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Heart valve replacement represents the most common surgical therapy for end-stage valvular heart
diseases. A major drawback that all contemporary heart valve replacements have in common is the
lack of growth, repair and remodelling capability. In order to overcome these limitations, the
emerging new field of tissue engineering is focusing on the in vitro generation of functional, living
heart valve replacements. The basic approach uses starter matrices either of decellularized
xenogeneic or polymeric materials configured in the shape of the heart valve and subsequent cell
seeding. This manuscript will give a detailed overview of these two concepts without giving favour to
one or the other. The concluding discussion will focus on current limitations and studies as well as
future challenges prior to safe clinical application.
Keywords: tissue engineering; heart valves; heart valve prosthesis; decellularized xenogeneic matrix;
biomaterials1. INTRODUCTION
The most common treatment for end-stage valvular
diseases is surgical replacement by either mechanical or
bioprosthetic heart valves. Mechanical valves display
good structural durability but are associated with the
risk of prosthetic valve endocarditis, and thromboem-
bolic complications caused by their non-physiological
surfaces and flow abnormalities. Life-long anticoagula-
tion therapy is necessary for these patients, associated
with a substantial risk of spontaneous bleeding and
embolism, particularly in patients over 70 years
(Senthilnathan et al. 1999).
Bioprosthetic heart valve replacements are either of
animal origin (xenografts), such as porcine aortic valves
and bovine pericardial valves, or taken from human
donors (homografts). Xenografts are chemically cross-
linked, which inhibits autolysis, enhances the mechanical
stability and creates the possibility of having valves
of different sizes stored and available off-the-shelf.
Unfortunately, these valves differ in many respects
from native valves, for example in their opening and
closing behaviour due to the above-mentioned chemical
pretreatment (Schoen & Levy 1999). The risk of
thromboembolic complications is much lower whentribution of 21 to a Theme Issue ‘Bioengineering the heart’.
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1505compared with mechanical prostheses but their dura-
bility is limited. Structural failure is strongly age
dependent, making them suitable primarily for the
elderly and less for children and young adults (Schoen &
Levy 1999). Cryopreserved donor valves are the
heart valve replacements closest to the natural valve,
being non-thrombogenic and having a low risk of
infection. They are not chemically cross-linked and
exhibit good mechanical properties (Lee & Mooney
2001). Disadvantages are their limited availability,
more difficult implantation techniques (Senthilnathan
et al. 1999) and failure associated with a specific
immune response, especially in young individuals
(Rajani et al. 1998).
Several attempts have been made to create functional
heart valve replacements, with the ability to grow, repair
and to remodel, using the concept of tissue engineering
(figure 1). In the tissue engineering approach, the
patient’s own cells isolated, e.g. from a blood vessel,
and expanded using standard cell culture techniques,
are seeded onto appropriate starter matrices, in the
shape of a heart valve. Appropriate starter matrices must
be able to support cell growth and cell-to-cell interaction
guiding the tissue formation into a functional organ with
organotypic extracellular matrix (ECM). The surfaces
of these starter vehicles must be biocompatible, allowing
cellular ingrowth and the formation of antithrombo-
genic layers. Currently, two principal types of starter
matrices have been applied for the tissue engineering
approach: xenogeneic or allogeneic decellularized fixed
heart valves and synthetic biodegradable polymers.This journal is q 2007 The Royal Society
(a) (b) (d ) (e)(c)
Figure 1. Overview of heart valve tissue engineering process: autologous cells are harvested from the patient (a) and isolated (b).
(c) After culturing and expanding in vitro, cells are seeded onto a heart valve starter matrix that could be polymeric or
xenogeneic. (d ) Seeded construct are positioned into a biomimetic system bioreactor and conditioned. (e) After in vitro
maturation, tissue-engineered heart valves are implanted into the patient. (Schmidt & Hoerstrup 2006)
1506 D. Schmidt et al. Tissue engineering of heart valves
 on December 8, 2009rstb.royalsocietypublishing.orgDownloaded from 2. TISSUE-ENGINEERED HEART VALVES BASED
ON DECELLULARIZED XENOGENEIC STARTER
MATRICES
One concept in heart-valve tissue engineering is to use
decellularized biologic matrices with autologous cell
reseeding. These matrices consist of allogeneic or
xenogeneic materials that are decellularized either
enzymatically or by detergent methods. As the
availability of autologous heart valves is limited in the
context of worldwide organ scarcity, current research
focuses on xenogeneic tissue. The decellularization
process is crucial as all cells need to be removed in
order to avoid any adverse cellular immune response
post-implantation. Conversely, the decellularization
process must also preserve the structural components
of the ECM relatively unaltered to provide a
biomechanically sufficient scaffold and foster efficient
reseeding. In a physiologic environment, ECM of heart
valves is continuously remodelled by matrix metallo-
proteinases (MMPs; Stock et al. 2001). Decellularized
matrices do not require ECM cross-linking protocols
such as glutaraldehyde fixation. This enables
degradation or metabolization by MMPs. At least
four different methods have been used to produce a
decellularized matrix. The most common approach is
an enzymatic cell removal (Steinhoff et al. 2000).
However, freeze drying (Curtil et al. 1997), osmotic
gradients (Wilson et al. 1995) and combinations
(Rieder et al. 2004) have been used as well. A recent
study demonstrated that complete decellularization of
porcine pulmonary heart valves with preservation of
the ECM architecture and subsequent ovine reseeding
is feasibile (Schenke-Layland et al. 2003a).(a) Decellularization of xenogeneic heart valves
using an enzymatic protocol
Even though the decellularization approach differs, the
general concept is rather similar. In general, donor
hearts (pig or sheep) are obtained under clean
conditions from a local abattoir within 15 min of
slaughter and are immediately transferred to the
laboratory. It is crucial to reduce the time between
slaughter and processing to minimize autolysis. For
in vivo trials, size-matched donor animals and sterile
harvest procedures are required. As porcine aortic
valves have a muscular attachment at the right coronary
leaflet, the majority of groups focus on either pulmon-
ary valves (PVs) or assemble a three-leaflet heart valve
from three non-coronary cusps. PVs are excised and
freed of adherent fat and most of the myocardium,
leaving only a thin ridge of subvalvular muscle tissuePhil. Trans. R. Soc. B (2007)and the pulmonary artery. In order to reduce potential
bacterial contamination, the valves are immediately
washed for 30 min at room temperature in antimicro-
bial solutions such as povidone–iodine solution and
sterile PBS followed by an overnight incubation at 48C
in an antibiotic solution (such as 1.2 mg amikacin;
3 mg flucytosin; 1.2 mg vancomycin; 0.3 mg ciproflox-
acin; and 1.2 mg metronidazol in 1 ml aqua ad inject).
Following this ‘antimicrobic pretreatment’ procedure,
the valves are ready for the actual decellularization
process. If this is achieved by enzymatic cell lysis, the
valves are placed in a solution of 0.05% trypsin and
0.02% EDTA at 378C and 5% CO2 for 24 h under
continuous three-dimensional shaking. Following cell
lysis, the cell detritus needs to be removed by a washing
step with PBS for another 24 h. The decellularized
valve matrices are finally stored in Hanks balanced salt
solution at 48C prior to further processing and seeding
(Schenke-Layland et al. 2003b, 2004).(b) Reseeding and dynamic culture protocol of
decellularized heart valves
Following expansion, cells equivalent to valve inter-
stitial cells, such as myofibroblasts, are trypsinized,
resuspended in culture medium and seeded onto the
decellularized PVs. The seeding normally requires a
repeated static drip seeding on the inner and outer
surface. In order to improve cell migration, prolifer-
ation and ECM production, mechanical load by means
of shear stress and/or strain has been applied to the
seeded valves in various bioreactors (Hoerstrup et al.
2000a; Mol et al. 2003; figure 2). This kind of
preimplantation conditioning requires exposure to
defined mechanical load over an extended time period
(e.g. 16 days). Shorter time periods would result in an
incomplete surface and cell ingrowth. Finally, endo-
thelial cells (EC) are seeded under static conditions,
allowing the cells to attach on the valve root and the
leaflets. The entire culture period is conducted in a
standard incubator at 378C and 5% CO2. A crucial
limitation of all long-term in vitro tissue engineering is a
constant risk of infections. Accordingly, sterile
handling is supported with repeated antibiotic supple-
ments (Schenke-Layland et al. 2003a).(c) In vivo evaluation of reseeded heart valves
In vivo evaluation of the decellularized reseeded heart
valves has been mainly performed in the pulmonary
circulation. As the clinical demand is focused on aortic
valves, we describe an animal model in the systemic
circulation of juvenile sheep. Carotid artery segments
pressure
vacuum AC/DC
pneumatic
controller
pressure
line and
monitor
inflow
gas mix
vacuum
pressure
valve closed
outflow
gas mix with
pressure release
60 cm
valve open
Figure 2. Schematic of a pulsatile bioreactor. The tissue-engineered heart valve (arrow) is perfused with nutrient media in a
pulsatile mode. The pulsatile flow is generated via a pneumatic system. Pressure conditions and gas exchange are monitored.
Figure 3. Autologous tissue-engineered heart valves before
implantation in an animal model. (Hoerstrup et al. 2000b)
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anatomical limitations, an orthotopic implantation of
the tissue-engineered valves is extremely complicated.
Accordingly, for an initial feasibility study, the valves
were implanted in the descending thoracic aorta. To
prevent distal ischaemia during cross-clamping, a
modified Gott shunt was established. A roller pump
maintained a distal perfusion of approximately 1.5 l
flow minK1 and a mean blood pressure of 35 mmHg.
Valve cusps in the descending aorta simply flutter
throughout the cardiac cycle due to the missing after-
load. A shunt between the distal aortic arch and the left
atrium was implanted to increase the aortic pulse
pressure by decreasing the diastolic pressure (Hilbert
et al. 1999). The placement of this shunt provides the
necessary haemodynamic conditions to enable
complete leaflet opening and coaptation.
An overall of six valves with autologous cell seeding
were implanted. Two valves were seeded explicitly with
EC and four with myofibroblasts and EC. All valves
were explanted at 12 weeks. Gross morphology showed
a smooth internal surface without thrombus formation
and no pathologic dilatation. Even though initial leaflet
movement was confirmed by Doppler echocardiogra-
phy and at the time of explantation the shunts were
operational, the leaflets did not move. A pathophysio-
logic explanation for this observation is an adaptation
of the sheep circulation.3. TISSUE-ENGINEERED HEART VALVES BASED
ON POLYMERIC STARTER MATRICES
The use of synthetic materials as starter matrix has
already been broadly demonstrated for cardiovascular
tissue engineering. An ideal synthetic material serves asPhil. Trans. R. Soc. B (2007)a temporary scaffold guiding tissue growth and
formation. It should be at least 90% porous (Agrawal &
Ray 2001) and must possess an interconnected pore
network that is essential for cell growth, nutrient supply
and removal of metabolic waste products. Currently,
several techniques have been used to fabricate such
porous structures, for example the salt-leaching
technique, weaving of fibre meshes, producing non-
woven meshes (Agrawal & Ray 2001; Hutmacher et al.
2001), rapid prototyping (Hutmacher et al. 2001), phase
separation (Nam & Park 1999) and electrospinning
1508 D. Schmidt et al. Tissue engineering of heart valves
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biodegradable and reproducible, the scaffold should
also exhibit a cell-favourable surface chemistry and
match the mechanical properties of the native tissue. In
order to guarantee mechanical stability over time, the
degradation rate of the scaffold should be controllable
and proportional to the rate of tissue formation.
Several synthetic biodegradable polymers, such as
polyglactin (Shinoka et al. 1995), polyglycolic acid
(PGA; Shinoka et al. 1996), polylactic acid (PLA;
Shinoka et al. 1998), polyhydroxyalkanoates (PHA;
Sodian et al. 2000a) and a copolymer of PGA and PLA
(PGLA; Zund et al. 1997), have been investigated as a
starter matrix for heart-valve tissue engineering.
(a) Aliphatic polyesters
Polyglactin, PGA and PLA belong to the family of
aliphatic polyesters, which degrade by cleavage of the
polymer chains by hydrolysis of their ester bonds. The
resulting monomer is either secreted in the urine or
enters the tricarboxylic acid cycle (Agrawal & Ray
2001). Initial attempts to create single heart-valve
leaflets were based on combinations of aliphatic
polyesters as well as, for example, woven polyglactin
and non-woven PGA meshes and layers of PLGA and
non-woven PGA meshes. The major limitations of
aliphatic polyesters are their thickness, initial stiffness
and non-pliability, making it difficult to fabricate a
trileaflet heart valve.
(b) Polyhydroxyalcanoates
The family of PHAs consists of polyesters built up from
hydroxyacids produced as intracellular granules by
various bacteria (Kessler & Withold 2001). Both
polyhydroxyoctanoate (Sodian et al. 2000b,c) and
poly-4-hydroxybutyrate (P4HB) have been used
(Sodian et al. 2000a,b) to create trileaflet heart-valve
conduits. These materials possess thermoplastic prop-
erties and can therefore be easily moulded into any
desired shape, as shown by using stereolithography
(Sodian et al. 2002). The general drawback of PHAs is
their slow degradation. Combinations of aliphatic
polyesters and PHAs have been tested as alternative
composite polymers (Hoerstrup 2000b; Stock et al.
2000; Rabkin et al. 2002). In particular, the use of PGA
coated with P4HB, combining the high porosity of PGA
and the thermoplastic properties of P4HB (Hoerstrup
2000b; Rabkin et al. 2002), for fabrication of complete
trileaflet heart valves has demonstrated promising
results in a rapidly growing sheep model (Hoerstrup
2000b).
(c) Proof-of-principle study
In a proof-of-principle study investigating a completely
autologous tissue-engineered heart valve based on
PGA/P4HB starter matrices in a long-term animal
model, the following experimental steps were per-
formed (Hoerstrup et al. 2000b).
Trileaflet heart-valve starter matrices were fabricated
from PGA/P4HB bioabsorbable polymers and sequen-
tially seeded with autologous ovine myofibroblasts
and EC. The constructs were grown for 14 days in a
pulse duplicator in vitro system under gradually
increasing flow and pressure conditions (figure 3).Phil. Trans. R. Soc. B (2007)Using cardiopulmonary bypass, the native pulmonary
leaflets were resected and the valve constructs were
implanted into six lambs (weightZ19G2.8 kg). All
animals had uneventful post-operative courses and the
valves were explanted at 1 day and 4, 6, 8, 16 and 20
weeks. Echocardiography demonstrated mobile, func-
tioning leaflets without stenosis, thrombus or aneurysm
up to 20 weeks. Histology showed uniform, layered
cuspal tissue with endothelium. Environmental scan-
ning electron microscopy revealed a confluent smooth
valve surface. Mechanical properties were comparable
to those of native tissue at 20 weeks. Complete
degradation of the polymers occurred in eight weeks.
The content of ECM (collagen, glycosaminoglycans
and elastin) and DNA increased to levels similar to
those of native tissue and were even higher at 20 weeks.
This study demonstrated in vitro generation of
implantable living heart valves based on a seeded
synthetic polymeric starter matrix preconditioned in a
biomimetic flow culture system. These autologous
tissue-engineered valves functioned for up to five
months in vivo and resembled normal heart valves
as to microstructure, mechanical properties and
ECM formation.
(d) From animal to human
As the principle of using synthetic starter matrices has
been carried out successfully in an animal model, the
methodology has been transferred to human in vitro
systems. In most cardiovascular tissue-engineering
approaches, cells are harvested from donor tissues,
e.g. from peripheral arteries and mixed vascular cell
populations consisting of myofibroblasts and EC. Out
of these, pure viable cell lines can be easily isolated by
cell sorters (Hoerstrup et al. 1998), and the sub-
sequent seeding onto the biodegradable starter
matrices is undertaken in two steps. First, the
myofibroblasts are seeded and grown in vitro. Second,
the EC are seeded on the surface of the generated
neo-tissue leading to the formation of a native-leaflet-
analogous histological structure. With regard to
clinical applications, several human cell sources have
been investigated. Among the most promising are
vascular-derived cells, bone-marrow-derived cells
(figure 4a–c), blood-derived cells (figure 4d–f ) and
umbilical-cord-derived cells, particularly for paediatric
application. Recently, cells derived from bone marrow
or umbilical cords have been successfully used to
generate heart valves (figure 5) and conduits in vitro
(Hoerstrup et al. 2002a,b). In contrast to vascular
cells, these cells can be obtained without surgical
interventions representing an easy-to-access cell
source in a possible routine clinical scenario. Owing
to their good proliferation and progenitor potential,
these cells are expected to be an attractive alternative
for cardiovascular tissue-engineering applications. In
recent studies, the use of umbilical-cord blood-derived
endothelial progenitor cells as a promising cell source
for paediatric cardiovascular tissue engineering has
been demonstrated, when they showed excellent
attachment to synthetic matrices PGA/P4HB
(Schmidt et al. 2004) as well as formation of living
endothelia on tissue-engineered patches and heart
valves based on PGA/P4HB starter matrices and
Tissue engineering of heart valves D. Schmidt et al. 1509
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villi-derived progenitor cells (Schmidt et al. 2005,
2006a,b).4. TISSUE-ENGINEERED HEART VALVES BASED
ON BIOLOGICAL/POLYMERIC HYBRID STARTER
MATRICES
A further strategy in tissue engineering that has recently
been introduced is the use of biological/polymeric
composite materials as starter matrices. Such hybrids
can be complex structures such as heart valves, e.g.
fabricated from decellularized porcine aortic valves and
dip coated with a biodegradable polymer (Stamm
2004). Moreover, scaffolds equipped with molecular
cues mimicking certain aspects of structure or function
of natural extracellular microenvironments have been
developed in recent years (Lutolf & Hubbell 2005).5. DISCUSSION
(a) Inflammation to matrix
Remaining issues include an inflammatory response
either as an immunological or foreign body reaction. In
2003, a group of cardiac surgeons in Vienna published
their catastrophic results of decellularized porcine heart
valves in paediatric patients (Simon et al. 2003). Three
of four patients died in the first year after surgical
treatment due to valve-related complications. Their
histology revealed severe inflammation from outside to
inside with subsequent degeneration. They further-
more identified areas of incomplete decellularization.
Whether the observed inflammation is to be seen as an
immunological or foreign body response to remaining
xenogeneic cells or ECM is subject to controversial
discussions and ongoing research.
(b) Safety of decellularized xenogeneic tissue
Another critical issue is the potential transmission of
microbiological hazards of xenotransplanted tissues,
such as porcine endogenous retroviruses and prionic
diseases. Recently, epidemiological data have strongly
indicated transfer of Creutzfeld-Jakob disease from
cattle into humans either via infected meat, surgical
material derived from bovine gut or drugs, or vaccines
prepared using foetal calf serum (Knight & Collins
2001). In contrast, a more recent study (Kallenbach
et al. 2004) revealed that transmission of porcine
endogenous retroviruses from pig to human is highly
unlikely.
(c) Preconditioning of tissue-engineered heart
valves prior to implantation
Mechanical and biological stimuli do interact in a very
complex way in the regulation of tissue behaviour. In
order to stimulate these interactions several con-
ditioning protocols have been developed. Mechanical
conditioning comprises the uses of mechanical stimuli
in in vitro bioreactors such as flow, shear stress or strain
applied to the developing tissue. For heart-valve tissue
engineering, the most commonly used bioreactor is a
pulse duplicator system mimicking the biological
environment and enabling the opening and closing
behaviour of the valve. Subsequent in vitro cultivation
providing biological (growth factors) or mechanicalPhil. Trans. R. Soc. B (2007)stimuli (bioreactors) promotes tissue development
(Niklason et al. 1999).
(d) Animal models for pulmonary and aortic
circulation
A worldwide established and accepted animal model
to test biological heart-valve devices in an in vivo
environment is the growing lamb. Lambs have the
fastest calcifying valvular system and the growth
dynamic of the heart and the great vessels are
equivalent to the human. Implantation of valvular
substitutes in the pulmonary circulation is relatively
easy to accomplish and has a low morbidity (Stock
et al. 2000). However, the evaluation of aortic heart
valves requires evaluation in the systemic circulation.
Owing to anatomical issues orthotopic implantation
in the subcoronary position of lamb is extremely
difficult and complicated by a high morbidity and
mortality rate. Alternative implantation sides focus on
the heterotopic descending aorta (Hilbert et al. 1999).
Even though initial success by means of competent
opening and closing throughout the cardiac cycle was
confirmed by ultrasound, mid-term function is
diminished due to adaptation of the animals to the
altered diastolic/systolic pressure gradient. Accor-
dingly, there might be a need to study different issues
of valve function and degeneration in different animal
models. One option is the investigation of calicifica-
tion in an ovine pulmonary circulation and biome-
chanical wear testing in the mitral position of pigs.6. FUTURE PERSPECTIVES
(a) What kind of valve will be required?
The concept of heart-valve tissue engineering was
initiated by paediatric surgeons. They were motivated
by the lack of adequate substitutes for patients with
absent or severely malformed native valve tissue. The
majority of these patients require valved conduits.
Implantation of these conduits, either isolated or as
pulmonary substitutes during pulmonary autograft
operations, requires great surgical skills, even in the
adult. As the complication rate is higher than in
prothestic or stented xenovalves, the worldwide accep-
tance of these valves shows a recent decrease. A tissue-
engineered living autologous valve with the capacity for
growth, repair and regeneration would overcome the
lack of appropriate replacement material and would
avoid reoperations.
The majority of patients requiring valve replacement
are older than 70 years. With increasing life expectancy,
more and more patients demand valvular substitutes
with long-term function exceeding that of currently
available glutaraldehyde-fixed biological valves. The
development of tissue-engineered heart valves based on
a stented design might be an important step in
achieving this goal.
Ideally, when tissue-engineering techniques are
introduced in future clinical routine, the schedule for
an older patient diagnosed with valvular disease may
be: (i) cell harvest by, for example, a bone marrow
puncture under local anaesthesia; (ii) differentiation
and expansion of the cells and tissue engineering of a
heart valve prosthesis in vitro; and (iii) following yet to
α-SMA
vimentin ac-LDL
vWF
native native
(a) (d )
(b) (e)
(c) ( f )
50×
400×
400×
100×1000×
50×
Figure 4. Human bone-marrow-derived cells 14 days after isolation (a), magnification 400!; expressing vimentin (b),
magnification 400!; and a-SMA (c), magnification 1000!; and human umbilical-cord blood-derived endothelial progenitor
cells 21 days after isolation (d ), magnification 50!; demonstrating ac-LDL uptake (e), magnification 50!; and von Willebrand
factor ( f ), magnification 100!, for fabrication of living autologous heart valves. (Hoerstrup et al. (2002a); Schmidt et al. (2004))
Figure 5. Tissue-engineered heart valve generated from
human marrow stromal cells. (Hoerstrup et al. (2002a))
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bio-safety, etc.), implantation of a living autologous
valve replacement into the patient after a time period of
six to eight weeks.REFERENCES
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